



**NMS Labs**

**CONFIDENTIAL**

200 Welsh Road, Horsham, PA 19044-2208  
Phone: (215) 657-4900 Fax: (215) 657-2972  
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

**Demo Report**

**Report Issued** 04/21/2022 17:43  
**Last Report Issued** 01/19/2015 12:14

**88888**  
Clinical Example Report  
Attn: Example Reports  
200 Welsh Road  
Horsham, PA 19044

**Patient Name** 2527U  
**Patient ID** 2527U  
**Chain** 15000135  
**DOB** Not Given  
**Sex** Not Given  
**Workorder** 15000135  
**Received** 01/19/2015

**Lab ID** 15000135-001  
**Matrix** Urine  
**Patient Name** 2527U  
**Patient ID** 2527U  
**Container Type** Clear vial

**Collect Dt/Tm** Not Given  
**Source** Not Given

**Approx Vol/Weight** Not Given

**Receipt Notes** None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

**2527U Lacosamide, Urine**

Analysis by High Performance Liquid Chromatography/  
Tandem Mass Spectrometry (LC-MS/MS)

Lacosamide	None Detected	mcg/mL	5.0	
Synonym(s): Vimpat®				

Lacosamide is a functionalized amino acid specifically synthesized as an anticonvulsant drug. In addition to being approved for use as an adjunctive therapy treatment of partial-onset seizures it has been investigated as a treatment for diabetic neuropathic pain. Lacosamide can be administered either orally or intravenously. The recommended initial dose is 50 mg/twice a day, up to a maintenance dose of 200 to 400 mg/day.

Single labeled oral or intravenous lacosamide doses in healthy subjects were eliminated in urine (95%) and feces (< 0.5%) over a 7 day interval. Urinary excretion products included parent drug (40% of the dose) and the pharmacologically inactive O-desmethyllacosamide.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.